DARE earnings date and last-quarter result: next report 2026-08-13, last quarter beat, P/E -1.17. Updated 2026-07-23.
Dare Bioscience (DARE) Research Hub
Dare Bioscience (DARE) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 0.6438 USD (-0.33%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.17, market cap 0.01B. This hub links to the full technical, earnings and options research available for DARE.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.6438 USD (-0.33%) |
| 52-week range | 0.625 USD – 2.21 USD |
| Trend regime | Range |
| 14-day RSI | 5.7 (Oversold) |
| Trailing P/E | -1.17 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for DARE
Covered Call on DARE: how it works, illustrative setup around the real 0.6438 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on DARE: how it works, illustrative setup around the real 0.6438 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on DARE: how it works, illustrative setup around the real 0.6438 USD price, max profit/loss, breakeven and when to use it. Educational.
DARE technical analysis: range, last 0.6438 USD, RSI 5.7, 52w range 0.625 USD–2.21 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is DARE in?
Dare Bioscience (DARE) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is DARE in an uptrend or downtrend?
As of 2026-10-26, DARE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is DARE's trailing P/E ratio?
DARE's trailing P/E is -1.17, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does DARE next report earnings?
DARE is next scheduled to report earnings on 2026-08-13.